Xeris Biopharma Holdings

Xeris Biopharma Holdings

XERS· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +131.6% in FY2025

John Shannon is the CEO of Xeris Biopharma Holdings and was paid $5.0M in FY2025 (Dec).

Pay$100 in the stock at the end of FY20 → $63
CEO pay is from each Xeris Biopharma Holdings proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1John ShannonFY2025
  2. 2Kevin McCullochFY2025
  3. 3Anh NguyenFY2025
  4. 4Beth P. HechtFY2025
  5. 5Steven M. PieperFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Xeris Biopharma Holdings paid its 5 named executives $13.1M in total in FY2025 (Dec). CEO John Shannon was paid $5.0M of that.

Name
John ShannonChief Executive Officer
Kevin McCullochPresident and Chief Operating OfficerNot disclosedNot disclosed
Anh NguyenChief Medical OfficerNot disclosedNot disclosed
Beth P. HechtChief Legal Officer and Corporate Secretary
Steven M. PieperChief Financial OfficerNot disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers16

See all

The FY2025 (Dec) proxy of Xeris Biopharma Holdings names 16 peer companies for pay. Pay versus performance data of Xeris Biopharma Holdings for that year is not on file, so it has no rank.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board1

See all
  • Jeffrey W. ShermanDirector · 3 yr on the boardIndependentCompensation, Nominating and Corporate Governance—Paid as an executive

The board of the latest proxy (FY2024).

Activity

Filings6

See all
Proxy statementDEF 14AApr 23, 2026FY2025
Annual report10-KMar 2, 2026FY2025
Proxy statementDEF 14AApr 23, 2025FY2024
Annual report10-KMar 6, 2025FY2024
Proxy statementDEF 14AApr 23, 2024FY2023
Annual report10-KMar 6, 2024FY2023